

# Santos Rd, Santos R

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7114207/publications.pdf>

Version: 2024-02-01

375  
papers

21,082  
citations

23500

58  
h-index

11581

135  
g-index

394  
all docs

394  
docs citations

394  
times ranked

18124  
citing authors

#	ARTICLE	IF	CITATIONS
1	Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society. <i>European Heart Journal</i> , 2013, 34, 3478-3490.	1.0	2,132
2	Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. <i>European Heart Journal</i> , 2015, 36, 1012-1022.	1.0	1,024
3	Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. <i>European Heart Journal</i> , 2014, 35, 2146-2157.	1.0	835
4	Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. <i>Lancet</i> , 2010, 375, 998-1006.	6.3	813
5	Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCR Working Group on Visceral Obesity. <i>Nature Reviews Endocrinology</i> , 2020, 16, 177-189.	4.3	790
6	Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 715-725.	5.5	687
7	Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. <i>European Heart Journal</i> , 2015, 36, 2425-2437.	1.0	644
8	The Agenda for Familial Hypercholesterolemia. <i>Circulation</i> , 2015, 132, 2167-2192.	1.6	539
9	Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients. <i>New England Journal of Medicine</i> , 2017, 376, 1527-1539.	13.9	510
10	The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 655-666.	5.5	473
11	Clinical Genetic Testing for Familial Hypercholesterolemia. <i>Journal of the American College of Cardiology</i> , 2018, 72, 662-680.	1.2	387
12	NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis. <i>Journal of the American College of Cardiology</i> , 2018, 71, 177-192.	1.2	337
13	Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 850-861.	5.5	329
14	Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. <i>International Journal of Cardiology</i> , 2014, 171, 309-325.	0.8	316
15	Familial hypercholesterolaemia. <i>Nature Reviews Disease Primers</i> , 2017, 3, 17093.	18.1	315
16	Uric acid: A marker of increased cardiovascular risk. <i>Atherosclerosis</i> , 2009, 202, 11-17.	0.4	310
17	Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab. <i>New England Journal of Medicine</i> , 2017, 376, 1517-1526.	13.9	307
18	A systematic review: Burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; Should we care?. <i>Atherosclerosis</i> , 2013, 230, 258-267.	0.4	301

#	ARTICLE	IF	CITATIONS
19	Lipid Treatment Assessment Project 2. <i>Circulation</i> , 2009, 120, 28-34.	1.6	293
20	An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia-Full report. <i>Journal of Clinical Lipidology</i> , 2014, 8, 29-60.	0.6	289
21	Homozygous familial hypercholesterolemia: Current perspectives on diagnosis and treatment. <i>Atherosclerosis</i> , 2012, 223, 262-268.	0.4	285
22	Predicting Cardiovascular Events in Familial Hypercholesterolemia. <i>Circulation</i> , 2017, 135, 2133-2144.	1.6	270
23	Adverse effects of statin therapy: perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. <i>European Heart Journal</i> , 2018, 39, 2526-2539.	1.0	262
24	Beyond BMI: The “Metabolically healthy obese” phenotype & its association with clinical/subclinical cardiovascular disease and all-cause mortality – a systematic review. <i>BMC Public Health</i> , 2014, 14, 14.	1.2	250
25	Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 280-290.	5.5	191
26	Reducing the Clinical and Public Health Burden of Familial Hypercholesterolemia. <i>JAMA Cardiology</i> , 2020, 5, 217.	3.0	169
27	Mipomersen, an Antisense Oligonucleotide to Apolipoprotein B-100, Reduces Lipoprotein(a) in Various Populations With Hypercholesterolemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 689-699.	1.1	165
28	III Diretrizes Brasileiras Sobre Dislipidemias e Diretriz de Prevenção da Aterosclerose do Departamento de Aterosclerose da Sociedade Brasileira de Cardiologia. <i>Arquivos Brasileiros De Cardiologia</i> , 0, 77, 1-48.	0.3	164
29	Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). <i>Atherosclerosis</i> , 2018, 277, 234-255.	0.4	163
30	Residual macrovascular risk in 2013: what have we learned?. <i>Cardiovascular Diabetology</i> , 2014, 13, 26.	2.7	149
31	Familial hypercholesterolaemia: A global call to arms. <i>Atherosclerosis</i> , 2015, 243, 257-259.	0.4	148
32	Phosphate Binder Impact on Bone Remodeling and Coronary Calcification – Results from the BRiC Study. <i>Nephron Clinical Practice</i> , 2008, 110, c273-c283.	2.3	146
33	Hepatic Steatosis, Obesity, and the Metabolic Syndrome Are Independently and Additively Associated With Increased Systemic Inflammation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011, 31, 1927-1932.	1.1	144
34	Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). <i>Lancet</i> , 2021, 398, 1713-1725.	6.3	142
35	Long-Term Evolocumab in Patients With Familial Hypercholesterolemia. <i>Journal of the American College of Cardiology</i> , 2020, 75, 565-574.	1.2	126
36	Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension. <i>European Heart Journal</i> , 2015, 36, 566-575.	1.0	114

#	ARTICLE	IF	CITATIONS
37	Association of Changes in Bone Remodeling and Coronary Calcification in Hemodialysis Patients: A Prospective Study. <i>American Journal of Kidney Diseases</i> , 2008, 52, 1139-1150.	2.1	112
38	Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia. <i>New England Journal of Medicine</i> , 2020, 383, 1317-1327.	13.9	108
39	Marked HDL deficiency and premature coronary heart disease. <i>Current Opinion in Lipidology</i> , 2010, 21, 289-297.	1.2	106
40	Coronary Artery Calcium and Cardiovascular Events in Patients With Familial Hypercholesterolemia Receiving Standard Lipid-Lowering Therapy. <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 1797-1804.	2.3	106
41	Long-term mipomersen treatment is associated with a reduction in cardiovascular events in patients with familial hypercholesterolemia. <i>Journal of Clinical Lipidology</i> , 2016, 10, 1011-1021.	0.6	104
42	The selective peroxisome proliferator-activated receptor alpha modulator (SPPARM $\alpha$ ) paradigm: conceptual framework and therapeutic potential. <i>Cardiovascular Diabetology</i> , 2019, 18, 71.	2.7	104
43	Integrated guidance on the care of familial hypercholesterolemia from the International FH Foundation. <i>Journal of Clinical Lipidology</i> , 2014, 8, 148-172.	0.6	98
44	Guideline for minimizing radiation exposure during acquisition of coronary artery calcium scans with the use of multidetector computed tomography. <i>Journal of Cardiovascular Computed Tomography</i> , 2011, 5, 75-83.	0.7	96
45	Blood pressure is associated with the presence and severity of nonalcoholic fatty liver disease across the spectrum of cardiometabolic risk. <i>Journal of Hypertension</i> , 2015, 33, 1207-1214.	0.3	90
46	Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration. <i>Atherosclerosis Supplements</i> , 2016, 22, 1-32.	1.2	90
47	Thoracic aorta calcification detected by electron beam tomography predicts all-cause mortality. <i>Atherosclerosis</i> , 2010, 209, 131-135.	0.4	87
48	Achievement of low-density lipoprotein cholesterol goals in 18 countries outside Western Europe: The International Cholesterol management Practice Study (ICLPS). <i>European Journal of Preventive Cardiology</i> , 2018, 25, 1087-1094.	0.8	86
49	ClinVar database of global familial hypercholesterolemia-associated DNA variants. <i>Human Mutation</i> , 2018, 39, 1631-1640.	1.1	84
50	Familial hypercholesterolaemia: evolving knowledge for designing adaptive models of care. <i>Nature Reviews Cardiology</i> , 2020, 17, 360-377.	6.1	82
51	Familial hypercholesterolemia in Brazil: Cascade screening program, clinical and genetic aspects. <i>Atherosclerosis</i> , 2015, 238, 101-107.	0.4	75
52	Effects of phytosterols on markers of inflammation: A systematic review and meta-analysis. <i>Atherosclerosis</i> , 2016, 248, 76-83.	0.4	74
53	Effect of open-label infusion of an apoA-I-containing particle (CER-001) on RCT and artery wall thickness in patients with FHA. <i>Journal of Lipid Research</i> , 2015, 56, 703-712.	2.0	73
54	Relation between visceral fat and coronary artery disease evaluated by multidetector computed tomography. <i>Atherosclerosis</i> , 2010, 209, 481-486.	0.4	70

#	ARTICLE	IF	CITATIONS
55	Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study. <i>Lancet, The</i> , 2022, 399, 719-728.	6.3	69
56	Evaluation of subclinical atherosclerosis by computed tomography coronary angiography and its association with risk factors in familial hypercholesterolemia. <i>Atherosclerosis</i> , 2010, 213, 486-491.	0.4	68
57	Does nonalcoholic fatty liver disease cause cardiovascular disease? Current knowledge and gaps. <i>Atherosclerosis</i> , 2019, 282, 110-120.	0.4	68
58	Relation of Uric Acid to Serum Levels of High-Sensitivity C-Reactive Protein, Triglycerides, and High-Density Lipoprotein Cholesterol and to Hepatic Steatosis. <i>American Journal of Cardiology</i> , 2012, 110, 1787-1792.	0.7	65
59	Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. <i>European Journal of Preventive Cardiology</i> , 2015, 22, 849-854.	0.8	60
60	Association of Body Mass Index, Metabolic Syndrome, and Leukocyte Count. <i>American Journal of Cardiology</i> , 2006, 97, 835-838.	0.7	58
61	Evaluating bococizumab, a monoclonal antibody to PCSK9, on lipid levels and clinical events in broad patient groups with and without prior cardiovascular events: Rationale and design of the Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) Lipid Lowering and SPIRE Cardiovascular Outcomes Trials. <i>American Heart Journal</i> , 2016, 178, 135-144.	1.2	58
62	Characterization of high density lipoprotein particles in familial apolipoprotein A-I deficiency. <i>Journal of Lipid Research</i> , 2008, 49, 349-357.	2.0	57
63	Relation of Aortic Valve Calcium Detected by Cardiac Computed Tomography to All-Cause Mortality. <i>American Journal of Cardiology</i> , 2010, 106, 1787-1791.	0.7	55
64	Presence and type of low density lipoprotein receptor (LDLR) mutation influences the lipid profile and response to lipid-lowering therapy in Brazilian patients with heterozygous familial hypercholesterolemia. <i>Atherosclerosis</i> , 2014, 233, 206-210.	0.4	55
65	Relation Between Self-Reported Physical Activity Level, Fitness, and Cardiometabolic Risk. <i>American Journal of Cardiology</i> , 2014, 113, 637-643.	0.7	52
66	No correlation and low agreement of imaging and inflammatory atherosclerosis markers in familial hypercholesterolemia. <i>Atherosclerosis</i> , 2008, 200, 83-88.	0.4	47
67	Thioredoxin interacting protein genetic variation is associated with diabetes and hypertension in the Brazilian general population. <i>Atherosclerosis</i> , 2012, 221, 131-136.	0.4	47
68	Defective functionality of small, dense HDL3 subpopulations in ST segment elevation myocardial infarction: Relevance of enrichment in lysophosphatidylcholine, phosphatidic acid and serum amyloid A. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2015, 1851, 1254-1261.	1.2	46
69	Relation of Uric Acid Levels to Presence of Coronary Artery Calcium Detected by Electron Beam Tomography in Men Free of Symptomatic Myocardial Ischemia With Versus Without the Metabolic Syndrome. <i>American Journal of Cardiology</i> , 2007, 99, 42-45.	0.7	45
70	Liver histology during Mipomersen therapy for severe hypercholesterolemia. <i>Journal of Clinical Lipidology</i> , 2014, 8, 606-611.	0.6	45
71	Free cholesterol transfer to high-density lipoprotein (HDL) upon triglyceride lipolysis underlies the U-shape relationship between HDL-cholesterol and cardiovascular disease. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 1606-1616.	0.8	45
72	Effect of Pravastatin on plasma removal of a chylomicron-like emulsion in men with coronary artery disease. <i>American Journal of Cardiology</i> , 2000, 85, 1163-1166.	0.7	44

#	ARTICLE	IF	CITATIONS
73	Obesity and Metabolic Phenotypes (Metabolically Healthy and Unhealthy Variants) Are Significantly Associated with Prevalence of Elevated C-Reactive Protein and Hepatic Steatosis in a Large Healthy Brazilian Population. <i>Journal of Obesity</i> , 2015, 2015, 1-6.	1.1	44
74	Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab. <i>Journal of Clinical Lipidology</i> , 2018, 12, 958-965.	0.6	44
75	Difference in atherosclerosis burden in different nations and continents assessed by coronary artery calcium. <i>Atherosclerosis</i> , 2006, 187, 378-384.	0.4	43
76	Targeting PCSK9 for therapeutic gains: Have we addressed all the concerns?. <i>Atherosclerosis</i> , 2016, 248, 62-75.	0.4	42
77	PCSK9 Inhibition With Monoclonal Antibodies: Modern Management of Hypercholesterolemia. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 7-32.	1.0	41
78	Lipid Lowering Drugs: Present Status and Future Developments. <i>Current Atherosclerosis Reports</i> , 2021, 23, 17.	2.0	41
79	Non-invasive detection of aortic and coronary atherosclerosis in homozygous familial hypercholesterolemia by 64 slice multi-detector row computed tomography angiography. <i>Atherosclerosis</i> , 2008, 197, 910-915.	0.4	40
80	Low- and high-density lipoprotein cholesterol goal attainment in dyslipidemic women: The Lipid Treatment Assessment Project (L-TAP) 2. <i>American Heart Journal</i> , 2009, 158, 860-866.	1.2	40
81	Calculated and perceived cardiovascular risk in asymptomatic subjects submitted to a routine medical evaluation: The perception gap. <i>European Journal of Preventive Cardiology</i> , 2015, 22, 1076-1082.	0.8	40
82	Characterizing familial chylomicronemia syndrome: Baseline data of the APPROACH study. <i>Journal of Clinical Lipidology</i> , 2018, 12, 1234-1243.e5.	0.6	40
83	Safety and efficacy of mipomersen in patients with heterozygous familial hypercholesterolemia. <i>Atherosclerosis</i> , 2019, 280, 109-117.	0.4	40
84	Subclinical coronary atherosclerosis: Racial profiling is necessary!. <i>American Heart Journal</i> , 2006, 152, 819-827.	1.2	38
85	Promoting a Syndemic Approach for Cardiometabolic Disease Management During COVID-19: The CAPISCO International Expert Panel. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 787761.	1.1	38
86	Insights into atherosclerosis from invasive and non-invasive imaging studies: Should we treat subclinical atherosclerosis?. <i>Atherosclerosis</i> , 2009, 205, 349-356.	0.4	37
87	An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia. <i>Atherosclerosis</i> , 2014, 232, 410-413.	0.4	36
88	Translational Research for Improving the Care of Familial Hypercholesterolemia: The "Ten Countries Study" and Beyond. <i>Journal of Atherosclerosis and Thrombosis</i> , 2016, 23, 891-900.	0.9	36
89	Health literacy in familial hypercholesterolemia: A cross-national study. <i>European Journal of Preventive Cardiology</i> , 2018, 25, 936-943.	0.8	36
90	Lomitapide and Mipomersen Inhibiting Microsomal Triglyceride Transfer Protein (MTP) and apoB100 Synthesis. <i>Current Atherosclerosis Reports</i> , 2019, 21, 48.	2.0	36

#	ARTICLE	IF	CITATIONS
91	The Progression and Impact of Vascular Calcification in Peritoneal Dialysis Patients. <i>Peritoneal Dialysis International</i> , 2007, 27, 340-346.	1.1	35
92	Clinical presentation, laboratory values, and coronary heart disease risk in marked high-density lipoprotein deficiency states. <i>Journal of Clinical Lipidology</i> , 2008, 2, 237-247.	0.6	35
93	A comparison of non-HDL and LDL cholesterol goal attainment in a large, multinational patient population: The Lipid Treatment Assessment Project 2. <i>Atherosclerosis</i> , 2012, 224, 150-153.	0.4	35
94	Prevalence, management, and outcomes of familial hypercholesterolemia in patients with acute coronary syndromes in the Arabian Gulf. <i>Journal of Clinical Lipidology</i> , 2018, 12, 685-692.e2.	0.6	35
95	Real-World Outcomes with Lomitapide Use in Paediatric Patients with Homozygous Familial Hypercholesterolaemia. <i>Advances in Therapy</i> , 2019, 36, 1786-1811.	1.3	35
96	Brazilian guidelines on prevention of cardiovascular disease in patients with diabetes: a position statement from the Brazilian Diabetes Society (SBD), the Brazilian Cardiology Society (SBC) and the Brazilian Endocrinology and Metabolism Society (SBEM). <i>Diabetology and Metabolic Syndrome</i> , 2017, 9, 53.	1.2	34
97	Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management. <i>Progress in Cardiovascular Diseases</i> , 2019, 62, 414-422.	1.6	34
98	Absence of Coronary Artery Calcification in Middle-Aged Familial Hypercholesterolemia Patients Without Atherosclerotic Cardiovascular Disease. <i>JACC: Cardiovascular Imaging</i> , 2020, 13, 1090-1092.	2.3	34
99	A obesidade e sua associao com os demais fatores de risco cardiovascular em escolares de Itapetininga, Brasil. <i>Arquivos Brasileiros De Cardiologia</i> , 2009, 93, 253-60.	0.3	34
100	Family history of coronary heart disease and markers of subclinical cardiovascular disease: Where do we stand?. <i>Atherosclerosis</i> , 2013, 228, 285-294.	0.4	32
101	Association between a healthy cardiovascular risk factor profile and coronary artery calcium score: Results from the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). <i>American Heart Journal</i> , 2016, 174, 51-59.	1.2	32
102	Comparative aspects of the care of familial hypercholesterolemia in the "Ten Countries Study". <i>Journal of Clinical Lipidology</i> , 2019, 13, 287-300.	0.6	32
103	Defective functionality of HDL particles in familial apoA-I deficiency: relevance of alterations in HDL lipidome and proteome. <i>Journal of Lipid Research</i> , 2014, 55, 2509-2520.	2.0	31
104	Reduced subclinical carotid vascular disease and arterial stiffness in vegetarian men: The CARVOS Study. <i>International Journal of Cardiology</i> , 2017, 230, 562-566.	0.8	31
105	Atorvastatin enhances the plasma clearance of chylomicron-like emulsions in subjects with atherogenic dyslipidemia: relevance to the in vivo metabolism of triglyceride-rich lipoproteins. <i>Atherosclerosis</i> , 2003, 166, 311-321.	0.4	30
106	Impaired intravascular triglyceride lipolysis constitutes a marker of clinical outcome in patients with stable angina undergoing secondary prevention treatment. <i>Journal of the American College of Cardiology</i> , 2004, 43, 2225-2232.	1.2	30
107	Prevalence, awareness, treatment, and control of high low-density lipoprotein cholesterol in Brazil: Baseline of the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). <i>Journal of Clinical Lipidology</i> , 2016, 10, 568-576.	0.6	30
108	Obstructive sleep apnea and effects of continuous positive airway pressure on triglyceride-rich lipoprotein metabolism. <i>Journal of Lipid Research</i> , 2018, 59, 1027-1033.	2.0	30

#	ARTICLE	IF	CITATIONS
109	Plasma kinetics of a cholesterol-rich emulsion in subjects with or without coronary artery disease. <i>Journal of Lipid Research</i> , 2003, 44, 464-469.	2.0	29
110	Cardiovascular and metabolic syndrome risk among men with and without erectile dysfunction: case-control study. <i>Sao Paulo Medical Journal</i> , 2010, 128, 137-140.	0.4	29
111	CXCR3 Controls T-Cell Accumulation in Fat Inflammation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, 1374-1381.	1.1	29
112	Familial hypercholesterolaemia: PCSK9 inhibitors are coming. <i>Lancet, The</i> , 2015, 385, 307-310.	6.3	29
113	National alert campaign about increased cholesterol: determination of cholesterol levels in 81,262 Brazilians. <i>Arquivos Brasileiros De Cardiologia</i> , 2003, 80, 635-638.	0.3	28
114	Achilles tendon xanthomas are associated with the presence and burden of subclinical coronary atherosclerosis in heterozygous familial hypercholesterolemia: A pilot study. <i>Atherosclerosis</i> , 2017, 263, 393-397.	0.4	27
115	Self-initiated physical activity is associated with high sensitivity C-reactive protein: A longitudinal study in 5,030 adults. <i>Atherosclerosis</i> , 2018, 273, 131-135.	0.4	27
116	Adherence to a Mediterranean diet, dyslipidemia and inflammation in familial hypercholesterolemia. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 2014-2022.	1.1	27
117	Hyperlipidemia related to the use of HIV-protease inhibitors: natural history and results of treatment with fenofibrate. <i>Brazilian Journal of Infectious Diseases</i> , 2001, 5, 332-8.	0.3	26
118	Association of Increased Cardiorespiratory Fitness with Low Risk for Clustering of Metabolic Syndrome Components in Asymptomatic Men. <i>Archives of Medical Research</i> , 2006, 37, 522-528.	1.5	26
119	Hepatic steatosis is associated with a greater prevalence of coronary artery calcification in asymptomatic men. <i>Atherosclerosis</i> , 2007, 194, 517-519.	0.4	26
120	High-normal fasting blood glucose in non-diabetic range is associated with increased coronary artery calcium burden in asymptomatic men. <i>Atherosclerosis</i> , 2007, 195, e155-e160.	0.4	26
121	Peripheral arterial disease in heterozygous familial hypercholesterolemia. <i>Atherosclerosis</i> , 2015, 242, 174-178.	0.4	26
122	Mipomersen preferentially reduces small low-density lipoprotein particle number in patients with hypercholesterolemia. <i>Journal of Clinical Lipidology</i> , 2015, 9, 201-209.	0.6	26
123	Relation of Fasting Triglyceride-Rich Lipoprotein Cholesterol to Coronary Artery Calcium Score (from the ELSA-Brasil Study). <i>American Journal of Cardiology</i> , 2017, 119, 1352-1358.	0.7	26
124	Delayed intravascular catabolism of chylomicron-like emulsions is an independent predictor of coronary artery disease. <i>Atherosclerosis</i> , 2004, 176, 397-403.	0.4	25
125	Cigarette smoking worsens systemic inflammation in persons with metabolic syndrome. <i>Diabetology and Metabolic Syndrome</i> , 2014, 6, 79.	1.2	25
126	Identification and Treatment of Patients with Homozygous Familial Hypercholesterolaemia: Information and Recommendations from a Middle East Advisory Panel. <i>Current Vascular Pharmacology</i> , 2015, 13, 759-770.	0.8	25

#	ARTICLE	IF	CITATIONS
127	Relation of Physical Activity to Prevalence of Nonalcoholic Fatty Liver Disease Independent of Cardiometabolic Risk. <i>American Journal of Cardiology</i> , 2015, 115, 34-39.	0.7	25
128	Elevated gamma-glutamyl transferase is associated with subclinical inflammation independent of cardiometabolic risk factors in an asymptomatic population: a cross-sectional study. <i>Nutrition and Metabolism</i> , 2016, 13, 37.	1.3	25
129	Evaluation of clinical and laboratory parameters used in the identification of index cases for genetic screening of familial hypercholesterolemia in Brazil. <i>Atherosclerosis</i> , 2017, 263, 257-262.	0.4	25
130	Prognostic utility of triglyceride-rich lipoprotein-related markers in patients with coronary artery disease. <i>Journal of Lipid Research</i> , 2020, 61, 1254-1262.	2.0	25
131	Pulse wave velocity a useful tool for cardiovascular surveillance in pre-dialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 3527-3532.	0.4	24
132	Severe Periodontitis Is Associated With Diastolic Blood Pressure Elevation in Individuals With Heterozygous Familial Hypercholesterolemia: A Pilot Study. <i>Journal of Periodontology</i> , 2011, 82, 683-688.	1.7	24
133	Lipid transfers to HDL are predictors of precocious clinical coronary heart disease. <i>Clinica Chimica Acta</i> , 2012, 413, 502-505.	0.5	24
134	What is new in familial hypercholesterolemia?. <i>Current Opinion in Lipidology</i> , 2014, 25, 183-188.	1.2	23
135	Delayed Heart Rate Recovery is Strongly Associated With Early and Late-Stage Prehypertension During Exercise Stress Testing. <i>American Journal of Hypertension</i> , 2014, 27, 514-521.	1.0	23
136	Proprotein Convertase Subtilisin Kexin Type 9 Inhibition for Autosomal Recessive Hypercholesterolemia—Brief Report. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 1647-1650.	1.1	23
137	Clinical and molecular aspects of familial hypercholesterolemia in Ibero-American countries. <i>Journal of Clinical Lipidology</i> , 2017, 11, 160-166.	0.6	23
138	Coronary Artery Calcification in Familial Hypercholesterolemia. <i>Circulation</i> , 2020, 142, 1405-1407.	1.6	23
139	Association of lipoprotein lipase D9N polymorphism with myocardial infarction in type 2 diabetes. <i>Atherosclerosis</i> , 2009, 204, 165-170.	0.4	22
140	Familial hypercholesterolemia prevalence in an admixed racial society: Sex and race matter. <i>The ELSA-Brasil</i> . <i>Atherosclerosis</i> , 2018, 277, 273-277.	0.4	22
141	Relation of serum uric acid with metabolic risk factors in asymptomatic middle-aged Brazilian men. <i>American Journal of Cardiology</i> , 2005, 95, 865-868.	0.7	21
142	Dyslipidemia according to gender and race: The Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). <i>Journal of Clinical Lipidology</i> , 2016, 10, 1362-1368.	0.6	21
143	Circulating PCSK9 levels are not associated with the conversion to type 2 diabetes. <i>Atherosclerosis</i> , 2020, 293, 49-56.	0.4	21
144	No benefit of HDL mimetic CER-001 on carotid atherosclerosis in patients with genetically determined very low HDL levels. <i>Atherosclerosis</i> , 2020, 311, 13-19.	0.4	21

#	ARTICLE	IF	CITATIONS
145	Posicionamento sobre o Consumo de Gorduras e SaÃºde Cardiovascular â€“ 2021. Arquivos Brasileiros De Cardiologia, 2021, 116, 160-212.	0.3	21
146	Is Coronary Artery Calcification Associated with Vertebral Bone Density in Nondialyzed Chronic Kidney Disease Patients?. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 1456-1462.	2.2	20
147	Elevated uric acid, the metabolic syndrome and cardiovascular disease: cause, consequence, or just a not so innocent bystander?. Endocrine, 2012, 41, 350-352.	1.1	20
148	Cascade Screening in Familial Hypercholesterolemia: Advancing Forward. Journal of Atherosclerosis and Thrombosis, 2015, 22, 869-880.	0.9	20
149	Effects of etofibrate upon the metabolism of chylomicron-like emulsions in patients with coronary artery disease. Atherosclerosis, 2001, 154, 455-461.	0.4	19
150	The Finnish Diabetes Risk Score (FINDRISC) as a screening tool for hepatic steatosis. Annals of Medicine, 2011, 43, 487-494.	1.5	19
151	Predictors of cardiovascular events after one year of molecular screening for Familial hypercholesterolemia. Atherosclerosis, 2016, 250, 144-150.	0.4	19
152	Global think tank on the clinical considerations and management of lipoprotein(a): The top questions and answers regarding what clinicians need to know. Progress in Cardiovascular Diseases, 2022, 73, 32-40.	1.6	19
153	Plasma kinetics of free and esterified cholesterol in familial hypercholesterolemia: Effects of simvastatin. Lipids, 2005, 40, 737-743.	0.7	18
154	Transfer of lipids to high-density lipoprotein (HDL) is altered in patients with familial hypercholesterolemia. Metabolism: Clinical and Experimental, 2013, 62, 1061-1064.	1.5	18
155	Is there a consistent association between coronary heart disease and ischemic stroke caused by intracranial atherosclerosis?. Arquivos De Neuro-Psiquiatria, 2013, 71, 320-326.	0.3	18
156	Statin-associated muscle symptoms: position paper from the Luso-Latin American Consortium. Current Medical Research and Opinion, 2017, 33, 239-251.	0.9	18
157	Effects of medication, treatment, and behavioral beliefs on intentions to take medication in patients with familial hypercholesterolemia. Atherosclerosis, 2018, 277, 493-501.	0.4	18
158	LDL concentration is correlated with the removal from the plasma of a chylomicron-like emulsion in subjects with coronary artery disease. Atherosclerosis, 2002, 161, 447-453.	0.4	17
159	Lipid goals among patients with diabetes or metabolic syndrome: Lipid Treatment Assessment Project (L-TAP) 2. Current Medical Research and Opinion, 2010, 26, 2589-2597.	0.9	17
160	Relation of Hepatic Steatosis to Atherogenic Dyslipidemia. American Journal of Cardiology, 2013, 112, 1599-1604.	0.7	17
161	Association between postprandial triglycerides and coronary artery disease detected by coronary computed tomography angiography. Atherosclerosis, 2014, 233, 381-386.	0.4	17
162	Association between Thyroid-Stimulating Hormone Levels and Non-Alcoholic Fatty Liver Disease Is Not Independent from Metabolic Syndrome Criteria. European Thyroid Journal, 2018, 7, 302-307.	1.2	17

#	ARTICLE	IF	CITATIONS
163	Low-density lipoprotein cholesterol goal achievement in patients with familial hypercholesterolemia in countries outside Western Europe: The International Cholesterol management Practice Study. <i>Journal of Clinical Lipidology</i> , 2019, 13, 594-600.	0.6	17
164	Case report: The efficacy and safety of lomitapide in a homozygous familial hypercholesterolemic child. <i>Journal of Clinical Lipidology</i> , 2019, 13, 397-401.	0.6	17
165	The challenge of multiple cardiovascular risk factor control outside Western Europe: Findings from the International Cholesterol management Practice Study. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 1403-1411.	0.8	17
166	The Role of Statins in Current Guidelines. <i>Current Atherosclerosis Reports</i> , 2020, 22, 50.	2.0	17
167	The Association of Subclinical Coronary Atherosclerosis With Abdominal and Total Obesity in Asymptomatic Men. <i>Preventive Cardiology</i> , 2005, 8, 59-62.	1.1	16
168	Increased level of cardiorespiratory fitness blunts the inflammatory response in metabolic syndrome. <i>International Journal of Cardiology</i> , 2006, 110, 224-230.	0.8	16
169	The MYLIP p.N342S polymorphism is associated with response to lipid-lowering therapy in Brazilian patients with familial hypercholesterolemia. <i>Pharmacogenetics and Genomics</i> , 2014, 24, 548-555.	0.7	16
170	Favorable effects of ezetimibe alone or in association with simvastatin on the removal from plasma of chylomicrons in coronary heart disease subjects. <i>Atherosclerosis</i> , 2014, 233, 319-325.	0.4	16
171	Phenotype vs. genotype in severe familial hypercholesterolemia: what matters most for the clinician?. <i>Current Opinion in Lipidology</i> , 2017, 28, 130-135.	1.2	16
172	Distinct phospholipid and sphingolipid species are linked to altered HDL function in apolipoprotein A-I deficiency. <i>Journal of Clinical Lipidology</i> , 2019, 13, 468-480.e8.	0.6	16
173	Vascular age derived from coronary artery calcium score on the risk stratification of individuals with heterozygous familial hypercholesterolaemia. <i>European Heart Journal Cardiovascular Imaging</i> , 2020, 21, 251-257.	0.5	16
174	Hypercholesterolemia Blunts Forearm Vasorelaxation and Enhances the Pressor Response During Acute Systemic Hypoxia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2003, 23, 1660-1666.	1.1	15
175	Metabolic Syndrome Is Associated With Coronary Artery Calcium in Asymptomatic White Brazilian Men Considered Low-Risk by Framingham Risk Score. <i>Preventive Cardiology</i> , 2007, 10, 141-146.	1.1	15
176	Combined Effect of High Low-Density Lipoprotein Cholesterol and Metabolic Syndrome on Subclinical Coronary Atherosclerosis in White Men Without Clinical Evidence of Myocardial Ischemia. <i>American Journal of Cardiology</i> , 2007, 100, 840-843.	0.7	15
177	Pre-historic eating patterns in Latin America and protective effects of plant-based diets on cardiovascular risk factors. <i>Clinics</i> , 2010, 65, 1049-1054.	0.6	15
178	Statin Use Is Not Associated With Presence of and Severity of Nonalcoholic Fatty Liver Disease. <i>Archives of Medical Research</i> , 2014, 45, 52-57.	1.5	15
179	Screening and management of familial hypercholesterolemia. <i>Current Opinion in Cardiology</i> , 2019, 34, 526-530.	0.8	15
180	Increased particle size of triacylglycerol-enriched remnant lipoproteins, but not their plasma concentration or lipid content, augments risk prediction of incident type 2 diabetes. <i>Diabetologia</i> , 2021, 64, 385-396.	2.9	15

#	ARTICLE	IF	CITATIONS
181	The Role of RNA-Targeted Therapeutics to Reduce ASCVD Risk: What Have We Learned Recently?. <i>Current Atherosclerosis Reports</i> , 2021, 23, 40.	2.0	15
182	Association of Peripheral Arterial and Cardiovascular Diseases in Familial Hypercholesterolemia. <i>Arquivos Brasileiros De Cardiologia</i> , 2014, 103, 118-23.	0.3	15
183	Phenotypical, Clinical, and Molecular Aspects of Adults and Children With Homozygous Familial Hypercholesterolemia in Iberoamerica. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 40, 2508-2515.	1.1	15
184	Algorithm for the treatment of type 2 diabetes: a position statement of Brazilian Diabetes Society. <i>Diabetology and Metabolic Syndrome</i> , 2010, 2, 35.	1.2	14
185	Screening and advanced lipid phenotyping in familial hypercholesterolemia: The Very Large Database of Lipids Study-17 (VLDL-17). <i>Journal of Clinical Lipidology</i> , 2015, 9, 676-683.	0.6	14
186	Low HDL cholesterol but not high LDL cholesterol is independently associated with subclinical coronary atherosclerosis in healthy octogenarians. <i>Aging Clinical and Experimental Research</i> , 2015, 27, 61-67.	1.4	14
187	Non-high-density lipoprotein cholesterol target achievement in patients on lipid-lowering drugs and stratified by triglyceride levels in the Arabian Gulf. <i>Journal of Clinical Lipidology</i> , 2016, 10, 368-377.	0.6	14
188	High-density Lipoprotein-cholesterol Subfractions and Coronary Artery Calcium: The ELSA-Brasil Study. <i>Archives of Medical Research</i> , 2019, 50, 362-367.	1.5	14
189	Self-Reported High-Cholesterol Prevalence in the Brazilian Population: Analysis of the 2013 National Health Survey. <i>Arquivos Brasileiros De Cardiologia</i> , 2017, 108, 411-416.	0.3	14
190	Atorvastatin Treatment Improves Myocardial and Peripheral Blood Flow in Familial Hypercholesterolemia Subjects without Evidence of Coronary Atherosclerosis. <i>Echocardiography</i> , 2013, 30, 64-71.	0.3	13
191	Recommendations for the Management of Patients with Familial Hypercholesterolemia. <i>Current Atherosclerosis Reports</i> , 2015, 17, 473.	2.0	13
192	Cholesterol and inflammation: The lesser the better in atherothrombosis. <i>European Journal of Preventive Cardiology</i> , 2018, 25, 944-947.	0.8	13
193	Predicting intention to participate in self-management behaviors in patients with Familial Hypercholesterolemia: A cross-national study. <i>Social Science and Medicine</i> , 2019, 242, 112591.	1.8	13
194	Association of Omnivorous and Vegetarian Diets With Antioxidant Defense Mechanisms in Men. <i>Journal of the American Heart Association</i> , 2020, 9, e015576.	1.6	13
195	Advances with lipid-lowering drugs for pediatric patients with familial hypercholesterolemia. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 483-495.	0.9	13
196	Non-alcoholic fatty liver disease and cardiovascular disease. <i>Atherosclerosis</i> , 2012, 224, 324-325.	0.4	12
197	C-reactive protein is independently associated with coronary atherosclerosis burden among octogenarians. <i>Aging Clinical and Experimental Research</i> , 2014, 26, 19-23.	1.4	12
198	Familial hypercholesterolemia and cardiovascular disease in older individuals. <i>Atherosclerosis</i> , 2021, 318, 32-37.	0.4	12

#	ARTICLE	IF	CITATIONS
199	The Effect of Bariatric Surgery on Circulating Levels of Oxidized Low-Density Lipoproteins Is Apparently Independent of Changes in Body Mass Index: A Systematic Review and Meta-Analysis. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-13.	1.9	12
200	The removal from plasma of chylomicrons and remnants is reduced in heterozygous familial hypercholesterolemia subjects with identified LDL receptor mutations: Study with artificial emulsions. <i>Atherosclerosis</i> , 2012, 221, 268-274.	0.4	11
201	Relevância da pré-hipertensão como categoria diagnóstica em adultos assintomáticos. <i>Einstein (Sao Paulo)</i> , 2011, 17, 107-114.	0.3	11
202	Expression of LDLRs (Low-Density Lipoprotein Receptors), Dyslipidemia Severity, and Response to PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) Inhibition in Homozygous Familial Hypercholesterolemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, 481-483.	1.1	11
203	Impact of Age on the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia. <i>Cardiovascular Drugs and Therapy</i> , 2019, 33, 69-76.	1.3	11
204	SPPARM alpha. <i>Current Opinion in Lipidology</i> , 2019, 30, 419-427.	1.2	11
205	LDL-cholesterol lowering and clinical outcomes in hypercholesterolemic subjects with and without a familial hypercholesterolemia phenotype: Analysis from the secondary prevention 4S trial. <i>Atherosclerosis</i> , 2021, 320, 1-9.	0.4	11
206	The Effects of Statin Dose, Lipophilicity, and Combination of Statins plus Ezetimibe on Circulating Oxidized Low-Density Lipoprotein Levels: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Mediators of Inflammation</i> , 2021, 2021, 1-12.	1.4	11
207	Prospective associations between multiple lifestyle behaviors and depressive symptoms. <i>Journal of Affective Disorders</i> , 2022, 301, 233-239.	2.0	11
208	Trends in the risk of mortality due to cardiovascular diseases in five Brazilian geographic regions from 1979 to 1996. <i>Arquivos Brasileiros De Cardiologia</i> , 2001, 77, 562-75.	0.3	10
209	Extensive Xanthomas and Severe Subclinical Atherosclerosis in Homozygous Familial Hypercholesterolemia. <i>Journal of the American College of Cardiology</i> , 2013, 61, 2193.	1.2	10
210	Impact of Fitness Versus Obesity on Routinely Measured Cardiometabolic Risk in Young, Healthy Adults. <i>American Journal of Cardiology</i> , 2013, 111, 991-995.	0.7	10
211	Lipoprotein(a) and Cardiovascular Disease in Heterozygous Familial Hypercholesterolemia. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1990-1991.	1.2	10
212	Association between high-density lipoprotein subfractions and low-grade inflammation, insulin resistance, and metabolic syndrome components: The ELSA-Brasil study. <i>Journal of Clinical Lipidology</i> , 2018, 12, 1290-1297.e1.	0.6	10
213	Impact of improved low-density lipoprotein cholesterol assessment on guideline classification in the modern treatment era—Results from a racially diverse Brazilian cross-sectional study. <i>Journal of Clinical Lipidology</i> , 2019, 13, 804-811.e2.	0.6	10
214	Metabolic health in Brazil: trends and challenges. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 937-938.	5.5	10
215	The risk of cardiometabolic disorders in lean non-alcoholic fatty liver disease: A longitudinal study. <i>American Journal of Preventive Cardiology</i> , 2020, 4, 100097.	1.3	10
216	Does physical activity influence the association between depressive symptoms and low-grade inflammation in adults? A study of 8,048 adults. <i>Physiology and Behavior</i> , 2020, 223, 112967.	1.0	10

#	ARTICLE	IF	CITATIONS
217	Atualiza�o da Diretriz Brasileira de Hipercolesterolemia Familiar � 2021. Arquivos Brasileiros De Cardiologia, 2021, 117, 782-844.	0.3	10
218	Effect of Bariatric Surgery on Flow-Mediated Vasodilation as a Measure of Endothelial Function: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine, 2022, 11, 4054.	1.0	10
219	Effects in post-menopausal women of transdermal estrogen associated with progestin upon the removal from the plasma of a microemulsion that resembles low-density lipoprotein (LDL). Maturitas, 2005, 50, 275-281.	1.0	9
220	Epicardial fat is associated with severity of subclinical coronary atherosclerosis in familial hypercholesterolemia. Atherosclerosis, 2016, 254, 73-77.	0.4	9
221	The relationship between migraine and lipid sub-fractions among individuals without cardiovascular disease: A cross-sectional evaluation in the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). Cephalalgia, 2018, 38, 528-542.	1.8	9
222	Physical activity levels and hepatic steatosis: A longitudinal follow-up study in adults. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 741-746.	1.4	9
223	Sex disparity in the management and outcomes of dyslipidemia of diabetic patients in the Arabian Gulf: findings from the CEPHEUS study. Lipids in Health and Disease, 2018, 17, 25.	1.2	9
224	Subclinical coronary atherosclerosis and cardiovascular risk stratification in heterozygous familial hypercholesterolemia patients undergoing statin treatment. Current Opinion in Lipidology, 2019, 30, 82-87.	1.2	9
225	The Finnish Diabetes Risk Score (FINDRISC), incident diabetes and low-grade inflammation. Diabetes Research and Clinical Practice, 2021, 171, 108558.	1.1	9
226	Past, Present, and Future of Familial Hypercholesterolemia Management. Methodist DeBakey Cardiovascular Journal, 2021, 17, 28-35.	0.5	9
227	Familial hypercholesterolemia and COVID-19: A menacing but treatable vasculopathic condition. Atherosclerosis Plus, 2021, 43, 3-6.	0.3	9
228	COVID-19 and Thromboinflammation: Is There a Role for Statins?. Clinics, 2021, 76, e2518.	0.6	9
229	Innovative Approaches to Assess Intermediate Cardiovascular Risk Subjects: A Review From Clinical to Metabolomics Strategies. Frontiers in Cardiovascular Medicine, 2021, 8, 788062.	1.1	9
230	Favorable Cardiovascular Risk Factor Profile Is Associated With Reduced Prevalence of Coronary Artery Calcification and Inflammation in Asymptomatic Nondiabetic White Men. Preventive Cardiology, 2008, 11, 189-194.	1.1	8
231	Vertebral bone density by quantitative computed tomography mirrors bone structure histomorphometric parameters in hemodialysis patients. Journal of Bone and Mineral Metabolism, 2013, 31, 551-555.	1.3	8
232	Familial hypercholesterolaemia: beware of lipoprotein(a). Lancet Diabetes and Endocrinology, the, 2016, 4, 553-555.	5.5	8
233	Association between clinical factors and self-underestimation of cardiovascular risk in subjects submitted to a routine health evaluation. Clinical Cardiology, 2018, 41, 28-33.	0.7	8
234	The prevalence and correlates of subclinical atherosclerosis among adults with low-density lipoprotein cholesterol < 70 mg/dL: The Multi-Ethnic Study of Atherosclerosis (MESA) and Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). Atherosclerosis, 2018, 274, 61-66.	0.4	8

#	ARTICLE	IF	CITATIONS
235	Inadequate control of atherosclerotic cardiovascular disease risk factors in Europe: EUROASPIRE repeats itself. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 820-823.	0.8	8
236	Very high LDL cholesterol: The power of zero passes another test. <i>Atherosclerosis</i> , 2020, 292, 207-208.	0.4	8
237	Branched-chain amino acids predict incident diabetes in the Brazilian Longitudinal Study of Adult Health "ELSA-Brasil. <i>Diabetes Research and Clinical Practice</i> , 2021, 174, 108747.	1.1	8
238	The association between coronary artery calcification progression and loss of bone density in non-dialyzed CKD patients. <i>Clinical Nephrology</i> , 2012, 78, 425-431.	0.4	8
239	Assessing the Accuracy of Estimated Lipoprotein(a) Cholesterol and Lipoprotein(a) Free Low-Density Lipoprotein Cholesterol. <i>Journal of the American Heart Association</i> , 2022, 11, e023136.	1.6	8
240	Screening of <i>ABCG5</i> and <i>ABCG8</i> Genes for Sitosterolemia in a Familial Hypercholesterolemia Cascade Screening Program. <i>Circulation Genomic and Precision Medicine</i> , 2022, 15, 101161CIRCGEN121003390.	1.6	8
241	Relationship of subclinical coronary atherosclerosis and National Cholesterol Education Panel guidelines in asymptomatic Brazilian men. <i>International Journal of Cardiology</i> , 2006, 108, 68-75.	0.8	7
242	Reaching C-Reactive Protein and Low-Density Lipoprotein Cholesterol Goals in Dyslipidemic Patients (from the Lipid Treatment Assessment Project [L-TAP] 2). <i>American Journal of Cardiology</i> , 2011, 107, 1639-1643.	0.7	7
243	Pericardial Fat Is Associated with Coronary Artery Calcification in Non-Dialysis Dependent Chronic Kidney Disease Patients. <i>PLoS ONE</i> , 2014, 9, e114358.	1.1	7
244	What are we able to achieve today for our patients with homozygous familial hypercholesterolaemia, and what are the unmet needs?. <i>Atherosclerosis Supplements</i> , 2014, 15, 19-25.	1.2	7
245	Europe aspires to set the record straight on familial hypercholesterolaemia. <i>Atherosclerosis</i> , 2015, 241, 769-771.	0.4	7
246	Extremely elevated HDL-cholesterol levels are not associated with increased carotid intima-media thickness: data from ELSA Brasil. <i>Journal of Clinical Lipidology</i> , 2016, 10, 898-904.e1.	0.6	7
247	Association of dietary components with dyslipidemia and low-grade inflammation biomarkers in adults with heterozygous familial hypercholesterolemia from different countries. <i>European Journal of Clinical Nutrition</i> , 2019, 73, 1622-1625.	1.3	7
248	Potential utility of the SAFEHEART risk equation for rationalising the use of PCSK9 monoclonal antibodies in adults with heterozygous familial hypercholesterolemia. <i>Atherosclerosis</i> , 2019, 286, 40-45.	0.4	7
249	EUROASPIRE V and uncontrolled risk factors in primary prevention: Atherosclerotic cardiovascular disease in the making. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 380-382.	0.8	7
250	Plasma proprotein convertase subtilisin/kexin type 9 concentration and recurrent cardiovascular events in patients with familial hypercholesterolemia. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 272-279.	0.8	7
251	Percepção Inadequada do Risco Cardiovascular e Baixo Conhecimento sobre Hipercolesterolemia Familiar em Indivíduos com Hipercolesterolemia Grave. <i>Arquivos Brasileiros De Cardiologia</i> , 2021, 116, 706-712.	0.3	7
252	Reconnoitering the Role of Long-Noncoding RNAs in Hypertrophic Cardiomyopathy: A Descriptive Review. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9378.	1.8	7

#	ARTICLE	IF	CITATIONS
253	Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus and Cardiovascular Disease: The Past, Present, and Future. <i>American Journal of Cardiovascular Drugs</i> , 2022, 22, 363-383.	1.0	7
254	Clinical practice gaps and challenges in non-alcoholic steatohepatitis care: An international physician needs assessment. <i>Liver International</i> , 2022, 42, 1772-1782.	1.9	7
255	Relation of Plasma Lipoprotein Levels With Low-Grade Inflammation in White Men Without Clinical Evidence of Myocardial Ischemia. <i>American Journal of Cardiology</i> , 2007, 100, 450-454.	0.7	6
256	Coronary calcification and coronary heart disease death rates in different countries, not only the influence of classical risk factors. <i>Atherosclerosis</i> , 2009, 202, 32-33.	0.4	6
257	The prevalence of the metabolically healthy obese phenotype in an aging population and its association with subclinical cardiovascular disease: The Brazilian study on healthy aging. <i>Diabetology and Metabolic Syndrome</i> , 2014, 6, 121.	1.2	6
258	Control of Risk Factors for Cardiovascular Disease among Multinational Patient Population in the Arabian Gulf. <i>Current Vascular Pharmacology</i> , 2016, 14, 374-381.	0.8	6
259	Review: PCSK9 inhibitors reduce mortality but increase neurocognitive events in hypercholesterolemia. <i>Annals of Internal Medicine</i> , 2016, 164, JC31.	2.0	6
260	Better health literacy can make the difference when control of risk factors for cardiovascular disease and quality of life are concerned. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 1878-1879.	0.8	6
261	Heterozygous familial hypercholesterolaemia in specialist centres in South Africa, Australia and Brazil: Importance of early detection and lifestyle advice. <i>Atherosclerosis</i> , 2018, 277, 470-476.	0.4	6
262	Diabetes alters the association between high-density lipoprotein subfractions and carotid intima-media thickness: The Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). <i>Diabetes and Vascular Disease Research</i> , 2018, 15, 541-547.	0.9	6
263	HDL Cholesterol Level and Mortality Occurrence in the Elderly: Is the Good Cholesterol Always Good?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 4114-4116.	1.8	6
264	The contribution of the systolic and diastolic components for the diagnosis of arterial hypertension under the 2017 ACC/AHA Guideline and metabolic heterogeneity among individuals with Stage 1 hypertension. <i>Journal of Clinical Hypertension</i> , 2020, 22, 1192-1199.	1.0	6
265	Beyond Statins and PCSK9 Inhibitors: Updates in Management of Familial and Refractory Hypercholesterolemias. <i>Current Cardiology Reports</i> , 2021, 23, 83.	1.3	6
266	Reference values for the triglyceride to high-density lipoprotein ratio and its association with cardiometabolic diseases in a mixed adult population: The ELSA-Brasil study. <i>Journal of Clinical Lipidology</i> , 2021, 15, 699-711.	0.6	6
267	Distribuição dos escores de risco coronariano determinados pela tomografia ultrassônica em 2.253 homens brancos assintomáticos. <i>Arquivos Brasileiros De Cardiologia</i> , 0, 81, 27-31.	0.3	6
268	Preventing the Next Pandemic: The Case for Investing in Circulatory Health – A Global Coalition for Circulatory Health Position Paper. <i>Global Heart</i> , 2021, 16, 66.	0.9	6
269	Cardiovascular Risk Stratification and Statin Eligibility Based on the Brazilian vs. North American Guidelines on Blood Cholesterol Management. <i>Arquivos Brasileiros De Cardiologia</i> , 2017, 108, 508-517.	0.3	6
270	Uric Acid and Cardiovascular Disease: How to Solve Another Chicken or Egg Puzzle. <i>Cardiology</i> , 2009, 114, 298-299.	0.6	5

#	ARTICLE	IF	CITATIONS
271	Comparison of Lipid Profiles and Attainment of Lipid Goals in Patients <65 Years Versus Patients ≥65 Years (from the Lipid Treatment Assessment Project [L-TAP] 2). American Journal of Cardiology, 2012, 109, 1738-1742.	0.7	5
272	Statin restores cardiac autonomic response to acute hypoxia in hypercholesterolaemia. European Journal of Clinical Investigation, 2013, 43, 1291-1298.	1.7	5
273	Apolipoprotein AI Deficiency Inhibits Serum Opacity Factor Activity against Plasma High Density Lipoprotein via a Stabilization Mechanism. Biochemistry, 2015, 54, 2295-2302.	1.2	5
274	Implications of the New US Cholesterol Guidelines in the Brazilian Longitudinal Study of Adult Health (ELSA-Brazil). Clinical Cardiology, 2016, 39, 215-222.	0.7	5
275	PCSK9 inhibition in type 2 diabetes: so far so good, but not there yet. Lancet Diabetes and Endocrinology, 2016, 4, 377-379.	5.5	5
276	Genetics and molecular biology controversies on Mendelian randomization and proprotein convertase subtilisin/kexin type 9 inhibitor clinical trials. Current Opinion in Lipidology, 2017, 28, 522-523.	1.2	5
277	Health related quality of life in individuals at high risk for familial hypercholesterolemia undergoing genetic cascade screening in Brazil. Atherosclerosis, 2018, 277, 464-469.	0.4	5
278	Gaps in beliefs and practice in dyslipidaemia management in Japan, Germany, Colombia and the Philippines: insights from a web-based physician survey. Lipids in Health and Disease, 2020, 19, 131.	1.2	5
279	Addressing Gaps in Racial/Ethnic Representation in Familial Hypercholesterolemia Registries. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e007306.	0.9	5
280	Risco Cardiovascular e Elegibilidade Para Estatina na Prevenção Primária: Comparação Entre a Diretriz Brasileira e a Diretriz da AHA/ACC. Arquivos Brasileiros De Cardiologia, 2020, 115, 440-449.	0.3	5
281	Association of dietary patterns and components with atherosclerosis risk biomarkers in familial hypercholesterolemia. Current Opinion in Lipidology, 2022, 33, 89-94.	1.2	5
282	Relationship between White Blood Cell Count and Framingham Risk Score in Asymptomatic Men. Archives of Medical Research, 2007, 38, 386-391.	1.5	4
283	Coronary Artery Calcification and Inflammation According to Various Metabolic Syndrome Definitions. Journal of the Cardiometabolic Syndrome, 2009, 4, 33-39.	1.7	4
284	Clinical perspective: Have the results of recent clinical trials of lipid-lowering therapies influenced the way we should practice? A Latin American perspective of current issues in clinical lipidology. Journal of Clinical Lipidology, 2011, 5, 124-132.	0.6	4
285	Detection of atherosclerotic cardiovascular disease influences the perceived need for aggressive lipid management. Atherosclerosis, 2017, 263, 112-118.	0.4	4
286	Statin Eligibility in Primary Prevention: From a Risk-Based Strategy to a Personalized Approach Based on the Predicted Benefit. American Journal of Cardiology, 2018, 121, 1315-1320.	0.7	4
287	Estimated costs of hospitalization due to coronary artery disease attributable to familial hypercholesterolemia in the Brazilian public health system. Archives of Endocrinology and Metabolism, 2018, 62, 303-308.	0.3	4
288	Residual vascular risk in diabetes – Will the SPPARM alpha concept hold the key?. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2019, 13, 2723-2725.	1.8	4

#	ARTICLE	IF	CITATIONS
289	Epicardial adipose tissue thickness and type 2 diabetes risk according to the FINDRISC modified for Latin America. <i>Clínica E Investigaci3n En Arteriosclerosis</i> , 2019, 31, 15-22.	0.4	4
290	Differences in HDL particle size in the presence of subclinical thyroid dysfunctions: The ELSA-Brasil study. <i>Atherosclerosis</i> , 2020, 312, 60-65.	0.4	4
291	Self-initiated changes in physical activity and incidence of Metabolic Syndrome: A longitudinal follow-up study. <i>Diabetes Research and Clinical Practice</i> , 2020, 165, 108224.	1.1	4
292	Unfavorable Triglyceride-rich Particle Profile in Subclinical Thyroid Disease: A Cross-sectional Analysis of ELSA-Brasil. <i>Endocrinology</i> , 2021, 162, .	1.4	4
293	Incidence and associated factors of type 2 diabetes mellitus onset in the Brazilian HIV/AIDS cohort study. <i>Brazilian Journal of Infectious Diseases</i> , 2021, 25, 101608.	0.3	4
294	Latin American Consensus on management of residual cardiometabolic risk. A consensus paper prepared by the Latin American Academy for the Study of Lipids and Cardiometabolic Risk (ALALIP) endorsed by the Inter-American Society of Cardiology (IASC), the International Atherosclerosis Society (IAS), and the Pan-American College of Endothelium (PACE). <i>Archivos De Cardiologia De Mexico</i> , 2021, 92, .	0.1	4
295	Menor Prevalência e Extensão da Aterosclerose Coronária na Doença de Chagas Clínica por Angiotomografia Coronária. <i>Arquivos Brasileiros De Cardiologia</i> , 2020, 115, 1051-1060.	0.3	4
296	Prevention of Cardiovascular Burden in COVID-19 Patients Suffering from Familial Hypercholesterolemia: A Global Challenge. <i>Cardiology and Therapy</i> , 2022, 11, 1-7.	1.1	4
297	Advancing Prediction of Pathogenicity of Familial Hypercholesterolemia LDL Receptor Commonest Variants With Machine Learning Models. <i>JACC Basic To Translational Science</i> , 2021, 6, 828-830.	1.9	4
298	PANDORA - Survey of Brazilian cardiologists about cholesterol reduction. <i>Arquivos Brasileiros De Cardiologia</i> , 2000, 75, 296-302.	0.3	3
299	Levels of lipoprotein (a) in pulmonary arterial hypertension. <i>Cardiology in the Young</i> , 2001, 11, 25-29.	0.4	3
300	Clearance of a 3H-labeled chylomicron-like emulsion following the acute phase of myocardial infarction. <i>International Journal of Cardiology</i> , 2004, 93, 181-187.	0.8	3
301	The Metabolic Syndrome Adds Incremental Value to the Framingham Risk Score in Identifying Asymptomatic Individuals With Higher Degrees of Inflammation. <i>Journal of the Cardiometabolic Syndrome</i> , 2008, 3, 7-11.	1.7	3
302	Coronary artery calcification progression and cardiovascular events in renal transplant recipients, bad inheritance from previous kidney disease: Commentary on the study of Roe et al.. <i>Atherosclerosis</i> , 2010, 212, 390-391.	0.4	3
303	Lipid-lowering treatment for homozygous familial hypercholesterolaemia. <i>Lancet, The</i> , 2013, 381, 1182.	6.3	3
304	Homozygous familial hypercholesterolemia: phenotype rules!. <i>Atherosclerosis</i> , 2016, 248, 252-254.	0.4	3
305	The Role of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Heart Failure, Regardless of Diabetes Status: Focus on Cardiovascular Disease. <i>Annals of Pharmacotherapy</i> , 2021, 55, 1267-1275.	0.9	3
306	Phospholipid transfer to high-density lipoprotein (HDL) upon triglyceride lipolysis is directly correlated with HDL-cholesterol levels and is not associated with cardiovascular risk. <i>Atherosclerosis</i> , 2021, 324, 1-8.	0.4	3

#	ARTICLE	IF	CITATIONS
307	Glycated Hemoglobin to Detect Subclinical Atherosclerosis in People Without Diabetes. Journal of the American College of Cardiology, 2021, 77, 2792-2795.	1.2	3
308	The Expected Cardiovascular Benefit of Plasma Cholesterol Lowering with or Without LDL-C Targets in Healthy Individuals at Higher Cardiovascular Risk. Arquivos Brasileiros De Cardiologia, 2017, 108, 518-525.	0.3	3
309	Predictors of Family Enrollment in a Genetic Cascade Screening Program for Familial Hypercholesterolemia. Arquivos Brasileiros De Cardiologia, 2018, 111, 578-584.	0.3	3
310	Challenges in familial chylomicronemia syndrome diagnosis and management across Latin American countries: An expert panel discussion. Journal of Clinical Lipidology, 2021, 15, 620-624.	0.6	3
311	Cardiometabolic disorders, inflammation and the incidence of non-alcoholic fatty liver disease: A longitudinal study comparing lean and non-lean individuals. PLoS ONE, 2022, 17, e0266505.	1.1	3
312	Challenges faced by patients with dyslipidemia and systemic arterial hypertension in Brazil: a design of the patient journey. BMC Cardiovascular Disorders, 2022, 22, .	0.7	3
313	Lipoprotein lipase does not affect lipoprotein (a) levels in normotriglyceridemic patients. International Journal of Cardiology, 1995, 50, 79-81.	0.8	2
314	Imaging biomarkers to track subclinical atherosclerosis in heterozygous familial hypercholesterolemia. Clinical Lipidology, 2013, 8, 231-242.	0.4	2
315	Impact of metabolic syndrome on lipid target achievements in the Arabian Gulf: findings from the CEPHEUS study. Diabetology and Metabolic Syndrome, 2016, 8, 49.	1.2	2
316	Association between non-alcoholic hepatic steatosis and hyper reactive blood pressure response on the exercise treadmill test. QJM - Monthly Journal of the Association of Physicians, 2016, 109, 531-537.	0.2	2
317	Increased subclinical atherosclerosis burden in familial hypercholesterolemia phenotype: What do genetic defects tell us and what are the clinical implications?. Atherosclerosis, 2017, 263, 316-317.	0.4	2
318	Lipoprotein(a) and cardiovascular mortality: mystery still unsolved. Lancet Diabetes and Endocrinology, 2017, 5, 489-490.	5.5	2
319	Metabolic syndrome, diabetes and inadequate lifestyle in first-degree relatives of acute myocardial infarction survivors younger than 45 years old. Lipids in Health and Disease, 2017, 16, 224.	1.2	2
320	Low-density lipoprotein cholesterol lowering in individuals at intermediate cardiovascular risk: Percent reduction or target level?. Clinical Cardiology, 2018, 41, 333-338.	0.7	2
321	Safety of statin treatment in children with familial hypercholesterolemia: Filling the gaps. Journal of Clinical Lipidology, 2018, 12, 12-15.	0.6	2
322	Mendelian randomization causally link lipoproteins to systemic atherosclerosis and help design clinical trials for the future of lipidology. Current Opinion in Lipidology, 2018, 29, 482-483.	1.2	2
323	Impact of self-reported fasting duration on lipid profile variability, cardiovascular risk stratification and metabolic syndrome diagnosis. Archives of Endocrinology and Metabolism, 2018, 62, 187-192.	0.3	2
324	Coronary Artery Calcification and Risk Stratification in Familial Hypercholesterolemia. JACC: Cardiovascular Imaging, 2021, 14, 2425-2428.	2.3	2

#	ARTICLE	IF	CITATIONS
325	Subclinical carotid vascular disease and risk factors for atherosclerosis in type 1 and type 2 diabetes. Archives of Endocrinology and Metabolism, 2017, 61, 105-107.	0.3	2
326	Calcified and Noncalcified Coronary Plaques and Atherosclerotic Cardiovascular Events in Patients With Severe Hypercholesterolemia—Moving Forward With Risk Stratification and Therapy. JAMA Network Open, 2022, 5, e2148147.	2.8	2
327	Effects of statins on specialized pro-resolving mediators: An additional pathway leading to resolution of inflammation. Metabolism: Clinical and Experimental, 2022, 132, 155211.	1.5	2
328	Coronary Artery and Thoracic Aorta Calcification and Cardiovascular Events in Severe Hypercholesterolemia: More Wood for the Cardiovascular Disease Risk Heterogeneity Bonfire!. Circulation: Cardiovascular Imaging, 2022, 15, .	1.3	2
329	A synergistic relationship of elevated low-density lipoprotein cholesterol levels and systolic blood pressure with coronary artery calcification. Atherosclerosis, 2008, 200, 368-373.	0.4	1
330	Commentary on the study of Laatsch et al. —Insulin stimulates hepatic low density lipoprotein receptor-related protein 1 (LRP1) to increase postprandial lipoprotein clearance— Atherosclerosis, 2009, 204, 112-113.	0.4	1
331	Increased resting heart rate and greater progression of subclinical coronary atherosclerosis: Another bad fact about fast hearts? Commentary on the study of Rubin et al.. Atherosclerosis, 2012, 220, 36-37.	0.4	1
332	ELEVATED GAMMA-GLUTAMYL TRANSFERASE IS INDEPENDENTLY ASSOCIATED WITH BURDEN OF SUBCLINICAL VASCULAR INFLAMMATION. Journal of the American College of Cardiology, 2013, 61, E1331.	1.2	1
333	Angiotensinogen gene polymorphism and HDL2 are linked to coronary artery calcification in individuals with family history of early coronary disease. Atherosclerosis, 2013, 226, 339-340.	0.4	1
334	Non Alcoholic Fatty Liver: Should We Care?. Current Cardiovascular Risk Reports, 2014, 8, 1.	0.8	1
335	Fatty liver, inflamed blood and calcified coronary arteries: Lessons and uncertainties from the multiethnic study of atherosclerosis -commentary on the study of Al Rifai et al.. Atherosclerosis, 2015, 239, 634-636.	0.4	1
336	Obesity Modifies the Effect of Fitness on Heart Rate Indices during Exercise Stress Testing in Asymptomatic Individuals. Cardiology, 2015, 132, 242-248.	0.6	1
337	Neutrophil to lymphocyte ratio and abdominal aortic atherosclerosis among asymptomatic individuals. Atherosclerosis, 2017, 263, e201.	0.4	1
338	Association of subclinical inflammation, glycated hemoglobin and risk for obstructive sleep apnea syndrome. Einstein (Sao Paulo, Brazil), 2017, 15, 136-140.	0.3	1
339	Treatment effect of alirocumab according to age group, smoking status, and hypertension: Pooled analysis from 10 randomized ODYSSEY studies. Journal of Clinical Lipidology, 2019, 13, 735-743.	0.6	1
340	Simon Broome confirms that the IAS definition of severe familial hypercholesterolemia predicts coronary mortality in patients with FH. Atherosclerosis, 2019, 281, 145-147.	0.4	1
341	Bringing interleukin-6 complexity to preventive cardiology practice?. European Journal of Preventive Cardiology, 2020, 27, 119-121.	0.8	1
342	Absence of coronary artery calcification and low rates not only of coronary and cardiovascular mortality: Can the power of zero be expanded beyond the vessels?. Atherosclerosis, 2020, 294, 44-45.	0.4	1

#	ARTICLE	IF	CITATIONS
343	Relationship between TSH Levels and the Advanced Lipoprotein Profile in the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). <i>Endocrine Research</i> , 2020, 45, 163-173.	0.6	1
344	Non-Alcoholic Fatty Liver Disease Modifies Serum Gamma-Glutamyl Transferase in Cigarette Smokers. <i>Journal of Clinical Medicine Research</i> , 2020, 12, 472-482.	0.6	1
345	Distribution of coronary artery calcium scores determined by ultrafast computed tomography in 2.253 asymptomatic white men. <i>Arquivos Brasileiros De Cardiologia</i> , 2003, 81 Suppl 7, 27-36.	0.3	1
346	Chronic inflammatory diseases, subclinical atherosclerosis, and cardiovascular diseases: Design, objectives, and baseline characteristics of a prospective case-cohort study - ELSA-Brasil. <i>Clinics</i> , 2022, 77, 100013.	0.6	1
347	Polygenic risk score for hypercholesterolemia in a Brazilian familial hypercholesterolemia cohort. <i>Atherosclerosis Plus</i> , 2022, 49, 47-55.	0.3	1
348	Commentary on the study of Rivera et al.: The relation of risk factors and total coronary artery plaque burden evaluated by multi-detector row computed tomography angiography. <i>Atherosclerosis</i> , 2009, 206, 349-350.	0.4	0
349	Plasma cholesterol is involved in the setting of resting blood pressure: A study in hypercholesterolemic young subjects and in monozygotic twins. <i>International Journal of Cardiology</i> , 2010, 144, 88-89.	0.8	0
350	Persistency of depression is associated with subclinical coronary atherosclerosis in males: Commentary on the study of Hamer et al.. <i>Atherosclerosis</i> , 2010, 210, 41-42.	0.4	0
351	Plaque regression measured by intravascular ultrasound and reduction of cardiovascular events: Not yet the case, commentary on the study of D'Ascenzo et al.. <i>Atherosclerosis</i> , 2013, 226, 45-46.	0.4	0
352	Validating the benefits of lipid modifying therapies upon atherosclerotic plaque by computed tomography angiography: Should we trust our eyes? Commentary on the study of Zeb et al.. <i>Atherosclerosis</i> , 2013, 231, 189-190.	0.4	0
353	Testosterone: A vascular hormone? Commentary on the study of Vlachopoulos et al.. <i>Atherosclerosis</i> , 2014, 233, 559-560.	0.4	0
354	ACC/AHA guidelines determining statin eligibility better predicted CVD than ATP-III guidelines. <i>Annals of Internal Medicine</i> , 2015, 163, JC11.	2.0	0
355	Computed tomography angiography defined vulnerable plaque in a patient with low high-density lipoprotein cholesterol and subsequent myocardial infarction. <i>Coronary Artery Disease</i> , 2017, 28, 712-714.	0.3	0
356	Heterozygous Familial Hypercholesterolaemia in Specialist Centres in South Africa, Australia and Brazil: Importance of Early Detection and Lifestyle Advice. <i>Atherosclerosis Supplements</i> , 2018, 32, 6.	1.2	0
357	Underdiagnosis, Undertreatment and Cardiovascular Risk Misperception among Individuals with Suspected Familial Hypercholesterolemia: a Brazilian Survey. <i>Atherosclerosis Supplements</i> , 2018, 32, 48.	1.2	0
358	Characterization of Elderly Individuals with Familial Hypercholesterolemia. <i>Atherosclerosis Supplements</i> , 2018, 32, 80.	1.2	0
359	Beware of early drug intolerance in secondary prevention of cardiovascular disease. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018, 4, 202-204.	1.4	0
360	Epicardial adipose tissue thickness and type 2 diabetes risk according to the FINDRISC modified for Latin America. <i>Clínica E Investigación En Arteriosclerosis (English Edition)</i> , 2019, 31, 15-22.	0.1	0

#	ARTICLE	IF	CITATIONS
361	Baseline LDL-C levels and risk of cardiovascular events: is there any room for questions?. International Journal of Cardiology, 2019, 286, 166-167.	0.8	0
362	Update on genetics and molecular biology. Current Opinion in Lipidology, 2019, 30, 414-416.	1.2	0
363	From the President of the International Atherosclerosis Society. Journal of Clinical Lipidology, 2020, 14, 613-614.	0.6	0
364	Vitamin C and primary prevention of cardiovascular disease: the case for Mendelian randomization. European Journal of Preventive Cardiology, 2022, 28, 1838-1839.	0.8	0
365	From the President of the International Atherosclerosis Society: The Iraqi Lipid Clinics Network. Journal of Clinical Lipidology, 2021, 15, 538-539.	0.6	0
366	Updates on genetics and molecular biology. Current Opinion in Lipidology, 2021, 32, 333-334.	1.2	0
367	High Density Lipoproteins, Dyslipidemia, and Heart Disease: Past, Present, and Future. , 2010, , 181-199.		0
368	Human Apolipoprotein A-I Deficiency. , 2010, , 55-61.		0
369	LDL Targeted Therapies. , 2011, , 605-619.		0
370	Commentary on "Association of Body Mass Index and Waist Circumference with Subclinical Atherosclerosis in Retired NFL Players". Southern Medical Journal, 2014, 107, 640-641.	0.3	0
371	Management of Homozygous Familial Hypercholesterolemia. Contemporary Cardiology, 2021, , 383-404.	0.0	0
372	OUP accepted manuscript. European Journal of Preventive Cardiology, 2021, , .	0.8	0
373	Physical Activity and HDL-C: Are There Gender Differences in the Dose-response Effect?. Arquivos Brasileiros De Cardiologia, 2021, 117, 501-502.	0.3	0
374	Pharmacological treatment with lipid-lowering agents after molecular identification of familial hypercholesterolemia: results from the Hipercol Brasil cohort. Journal of Clinical Lipidology, 2022, , .	0.6	0
375	Substantially elevated TSH, not traditional clinical subclinical thyroid disorder groupings, are associated with smaller LDL-P mean size: ELSA-Brasil. Journal of Clinical Lipidology, 2022, , .	0.6	0